Global Flow Cytometry Market Market Trends
Growing demand for effective testing techniques
The increasing global incidence of infectious diseases is an additional factor propelling the use of flow cytometry methods. Over 4.5 million people die from AIDS and tuberculosis each year; effective immunophenotyping and cell isolation techniques are crucial to reducing these illnesses' impact. By employing this technique, pathogenic microbes can be readily identified from environmental samples and can provide a viable option for immunophenotyping.
Given the high prevalence of infectious diseases in low- and lower-middle-income nations, it is expected that the need for highly effective testing methods, like flow cytometry, will grow as long as mortality from newly and re-emerging infectious diseases continues to rise.
Funding and investments in R&D have produced a robust R&D infrastructure in the fields of biotechnology, biopharmaceutical, clinical and biological sciences studies. This will enhance research and development (R & D) in the area of cell analysis for new drug discovery and development activities using flow cytometry techniques. Additionally, the most recent flow cytometry instrumentation is becoming more accurate, efficient, and cost-effective due to technological advancements, which is predicted to open up new growth opportunities for the industry.
As an example, Pfizer Inc. made a USD 120 million investment in biotechnology innovation in January 2021 through the Pfizer Breakthrough Growth Initiative (PBGI).
Limits on the Flow Cytometry Market:
Insufficient Expertise & Exorbitant Maintenance Expenses
The flow cytometry market has a number of limitations that could prevent it from reaching its full potential, despite the substantial growth opportunities. One significant obstacle is the high price of flow cytometry equipment. reagents and upkeep, which may restrict adoption, especially in environments with limited resources, like developing nations and smaller research facilities. Furthermore, the intricacy of flow cytometry data analysis and instrumentation may present difficulties for users needing more specialized training, thereby restricting the broad acceptance and application of the technology. The market expansion of flow cytometry-based diagnostic tests is hindered by regulatory obstacles and reimbursement constraints. These tests need to undergo thorough validation and clinical utility demonstration in order to obtain regulatory approval and reimbursement coverage.